The University of Virginia Comprehensive Cancer Center seeks patients ages 18 and over with Refractory SPOP-mutant Prostate Cancer for a research study. The study will evaluate an investigational drug called M1774 to see if M1774 is effective at treating your cancer. M1174 is considered investigational because it is no yet approved by the FDA to treat this disease. The purpose of this study is to learn if the M1774 will stabilize or shrink your cancer.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with Advanced KRAS Mutated Cholangiocarcinoma (CCA) to participate in a research study. This study will evaluate the safety and efficacy of GNS561 given in combination with trametinib. The study drugs GNS561 and trametinib in combination are considered investigational, which means that the combination has not been approved by the United States Food and Drug Administration, for the treatment of patients with CCA. The study includes 2 parts.

The Pediatric Hematology/Oncology Division at the University of Virginia is conducting a clinical research study for pediatric patients who have been diagnosed with newly diagnosed Stage 1 & 2 Classic Hodgkin Lymphoma. This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have been diagnosed with TP53 wild-type endometrial carcinoma and had a response to prior systemic chemotherapy. The purpose of this study is to evaluate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer. Selinexor is a medicine that is FDA approved for Multiple Myeloma and Diffuse large B-cell lymphoma but is not yet approved for endometrial cancer (EC). This means the study drug is considered investigational for use with EC.

The Contrast Mammography Imaging Screening Trial, or CMIST is comparing two methods of mammography to help women and their doctors decide the best ways to screen for breast cancer in the future.
The CMIST research study will follow women already planned to get three-dimensional (3D) tomosynthesis screening mammography routinely for breast cancer.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have newly diagnosed advanced-stage ovarian, fallopian tube or primary peritoneal cancer scheduled to receive neoadjuvant chemotherapy. The purpose of this study is to evaluate the feasibility of receiving chemotherapy with Carboplatin and the investigational drug called Mirvetuximab soravtansine as first-line treatment in subjects that are Folate receptor positive.

The Anesthesiology Department at UVA seeks healthy adults, ages 65 to 90 years-old, with no severe/debilitating medical conditions for a research study. The purpose of the study is to determine why caregivers of patients with Alzheimer’s Disease have a higher rate of developing dementia than the general population.

You may be eligible for this study if: 1. You do not have any major neurological, cardiac, kidney, or liver disease. 2. Your life expectancy is not shorter than 3 months. 3. You have not previously participated in this study.

The Division of Endocrinology seeks adults ages 18 to 40 years with type 1 diabetes for a research study. The purpose of the study is to learn more about how a medicine called Trulicity or exercise training impact cardiovascular health and blood sugar control.

You may be eligible for this study if you have type 1 diabetes and are otherwise healthy and do not smoke.

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). The purpose of this study is to test the safety and efficacy of tolinapant and INQOVI (decitabine and cedazuridine). This is a 3-part study:
• Part 1 (Lead-in) will determine the starting dose of oral decitabine/ cedazuridine tablet
• Part 2 (Phase 1) will help determine the doses and safety of the study drugs in combination

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutation.